Dicot Pharma receives approval to start Phase 2a clinical trial
Uppsala, Sweden, October 21, 2024. Today, the pharmaceutical company Dicot Pharma was granted authorization to start its clinical phase 2a study which will be conducted in Sweden, Denmark, and the Netherlands. It is a placebo-controlled trial with the primary objective to evaluate the efficacy of the potency drug candidate LIB-01 in patients with erectile dysfunction.Dicot Pharma's second study in humans with the potency drug candidate LIB-01 has now received regulatory authorization from all relevant authorities in Sweden, Denmark, and the Netherlands. Preparations for the study are